Sierra Oncology
1820 Gateway Drive
Suite 110
San Mateo
California
94404
United States
Tel: 650-376-8679
Website: https://sierraoncology.com/
About Sierra Oncology
194 articles with Sierra Oncology
-
When GSK’s consumer health spinoff Haleon launches later this month, the new business will carry more than $12 billion in debt when it lists on the London Stock Exchange.
-
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
6/17/2022
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib.
-
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
5/26/2022
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3-7, 2022, in Chicago and online.
-
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
5/12/2022
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association (EHA)
-
Sierra Oncology Reports First Quarter 2022 Results
5/6/2022
Sierra Oncology, Inc. today reported its financial and operating results for the first quarter ended March 31, 2022.
-
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 05, 2022
5/5/2022
Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twelve new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.
-
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
4/13/2022
GlaxoSmithKline plc and Sierra Oncology, Inc announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion.
-
GSK is acquiring Sierra Oncology for $1.9 billion in a deal expected to help both companies take a major step in developing a treatment for rare types of cancer.
-
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 06, 2022
4/6/2022
Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to seven new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.
-
Sierra Oncology to Participate in the Oppenheimer 32nd Annual Healthcare Conference
3/11/2022
Sierra Oncology, Inc. today announced the company will participate in the 32nd Annual Oppenheimer Healthcare Conference being held virtually from March 15-17, 2022.
-
Sierra Oncology Reports 2021 Year End Results
3/10/2022
Sierra Oncology, Inc. today reported its financial and operating results for the fourth quarter and fiscal year ended December 31, 2021.
-
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Mar 04, 2022
3/4/2022
Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies that treat rare forms of cancer, granted stock options to six new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.
-
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Feb 18, 2022
2/18/2022
Sierra Oncology, Inc., a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted a stock option to one new employee as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.
-
Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/3/2022
Sierra Oncology, Inc today announced that the underwriters of its previously announced underwritten public offering exercised in full their option to purchase 750,000 additional shares of common stock at a price of $27.00 per share.
-
Sierra Oncology to Participate in Guggenheim Oncology Conference
2/3/2022
Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, announced the company will participate in the 4th Annual Guggenheim Oncology Conference being held virtually from February 9 – 11, 2022.
-
Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities
1/31/2022
Sierra Oncology, Inc. today announced the closing of its previously announced underwritten public offering of 4,074,075 shares of its common stock at a price to the public of $27.00 per share.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
1/27/2022
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 B. Riley Securities Oncology Investor Conference being held virtually from January 27-28, 2022.
-
Sierra Oncology Announces Pricing of Upsized Public Offering of Securities
1/27/2022
Sierra Oncology, Inc. announced the pricing of an upsized underwritten public offering of 4,074,075 shares of its common stock and, in lieu of shares of common stock, to a certain investor, pre-funded warrants to purchase up to 925,925 shares of common stock pursuant to its existing shelf registration statement.
-
Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib
1/25/2022
Sierra Oncology, Inc. today announced it has entered into a term loan agreement with Oxford Finance, LLC that is designed to primarily support the commercial preparation and potential launch of momelotinib, an investigational agent for the treatment of myelofibrosis, a rare form of blood cancer.